Anika Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
$0.41next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Company Revenue Quarterly29.6MTarget: $114.0 million to $122.5 million
Gross Margin Quarterly64.2%Target: Margin expansion driven by operational execution and lean initiatives
Commercial Channel Revenue Quarterly12.6MTarget: $53.0 million to $58.0 million (10% to 20% growth)
OEM Channel Revenue Quarterly17MTarget: $61.0 million to $64.5 million (flat to down 5%)
Adjusted EBITDA Margin AnnuallyTarget: 5% to 10% of revenue
Watch Items
- Hyalofast FDA PMA ApprovalTrigger: Submission of responses to FDA deficiency letter (received Jan 2026)Action: Monitor regulatory timeline and preparation of commercial infrastructure for potential late 2027 U.S. launch.
- Cingal FDA NDA PreparationTrigger: Completion of the ongoing bioequivalence studyAction: Track enrollment progress and clinical data generation to establish a definitive NDA filing window.
- OEM Channel Pricing PressuresTrigger: Contract renewals and pricing dynamics with major partners like J&J MedTechAction: Assess impact on gross margins and offset potential declines through Commercial Channel expansion (e.g., Integrity platform).
Research as of 19 Jun 2026